Lexeo Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 59

Employees

  • Stock Symbol
  • LXEO

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.96
  • (As of Friday Closing)

Lexeo Therapeutics General Information

Description

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Contact Information

Website
www.lexeotx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 345 Park Avenue South
  • 6th Floor
  • New York, NY 10010
  • United States
+1 (212)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 345 Park Avenue South
  • 6th Floor
  • New York, NY 10010
  • United States
+1 (212)

Lexeo Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lexeo Therapeutics Stock Performance

As of 20-Nov-2026, Lexeo Therapeutics’s stock price is $2.96. Its current market cap is $245M with 82.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.96 $2.95 $2.55 - $10.99 $245M 82.8M 1.96M -$1.26

Lexeo Therapeutics Financials Summary

As of 30-Sep-2026, Lexeo Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 72,566 610,457 71,033 523,375
Revenue 0 0 0 0
EBITDA (111,658) (103,806) (103,773) (67,213)
Net Income (105,282) (99,961) (98,333) (66,394)
Total Assets 243,916 268,688 146,942 139,807
Total Debt 6,247 7,886 9,924 11,638
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexeo Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lexeo Therapeutics‘s full profile, request access.

Request a free trial

Lexeo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Lexeo Therapeutics‘s full profile, request access.

Request a free trial

Lexeo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidate
Drug Discovery
New York, NY
59 As of 2025

Charlestown, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lexeo Therapeutics Competitors (20)

One of Lexeo Therapeutics’s 20 competitors is Solid Biosciences, a Formerly VC-backed company based in Charlestown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Solid Biosciences Formerly VC-backed Charlestown, MA
Tenaya Therapeutics Formerly VC-backed South San Francisco, CA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Prime Medicine Formerly VC-backed Cambridge, MA
Taysha Gene Therapies Formerly VC-backed Dallas, TX
You’re viewing 5 of 20 competitors. Get the full list »

Lexeo Therapeutics Patents

Lexeo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023215308-A1 Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia Pending 01-Feb-2022
EP-4472674-A1 Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia Pending 01-Feb-2022
US-20250161483-A1 Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia Pending 01-Feb-2022
WO-2023150563-A1 Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia Inactive 01-Feb-2022 A61K48/0033

Lexeo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lexeo Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lexeo Therapeutics‘s full profile, request access.

Request a free trial

Lexeo Therapeutics Acquisitions (2)

Lexeo Therapeutics’s most recent deal was a Merger/Acquisition with Mantle Therapeutics for . The deal was made on 23-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Mantle Therapeutics 23-Sep-2026 Merger/Acquisition Drug Discovery
Stelios Therapeutics 16-Jul-2021 Merger/Acquisition Drug Discovery
To view Lexeo Therapeutics’s complete acquisitions history, request access »

Lexeo Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.62 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Lexeo Therapeutics’s complete esg history, request access »

Lexeo Therapeutics FAQs

  • When was Lexeo Therapeutics founded?

    Lexeo Therapeutics was founded in 2018.

  • Where is Lexeo Therapeutics headquartered?

    Lexeo Therapeutics is headquartered in New York, NY.

  • What is the size of Lexeo Therapeutics?

    Lexeo Therapeutics has 59 total employees.

  • What industry is Lexeo Therapeutics in?

    Lexeo Therapeutics’s primary industry is Drug Discovery.

  • Is Lexeo Therapeutics a private or public company?

    Lexeo Therapeutics is a Public company.

  • What is Lexeo Therapeutics’s stock symbol?

    The ticker symbol for Lexeo Therapeutics is LXEO.

  • What is the current stock price of Lexeo Therapeutics?

    As of 20-Nov-2026 the stock price of Lexeo Therapeutics is $2.96.

  • What is the current market cap of Lexeo Therapeutics?

    The current market capitalization of Lexeo Therapeutics is $245M.

  • Who are Lexeo Therapeutics’s competitors?

    Solid Biosciences, Tenaya Therapeutics, Intellia Therapeutics, Prime Medicine, and Taysha Gene Therapies are some of the 20 competitors of Lexeo Therapeutics.

  • What is Lexeo Therapeutics’s annual earnings per share (EPS)?

    Lexeo Therapeutics’s EPS for 12 months was -$1.26.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process